摘要
血管收缩素(Ang )-(1-7) 在高血压蛋白原酶血管收缩素系统(地岬) 作为新 bioactive 肽被认出。Ang-(1-7 ) 是看起来对心血管的疾病保护的 Ang-II 的一个柜台规章的调停人。最近的研究发现了 Ang-(1-7 ) 在减少光滑的肌肉房间增长和移植起了一个重要作用，改进 endothelial 功能并且调整类脂化合物新陈代谢，导致动脉粥样硬化患者损害的抑制和匾稳定性的增加。尽管 Ang-(1-7 ) 的临床的申请由于它的 pharmacokinetic 性质被限制，包括更稳定的类似物和特定的交货混合物，稳定的混合物的鉴定启用了 Ang-(1-7 ) 的临床的申请。在这评论，我们在动脉粥样硬化开发期间有关 Ang-(1-7 ) 和相关机制的生物角色讨论了最近的调查结果。另外，我们加亮观点用 Ang-(1-7 ) 开发治疗学的策略对待动脉粥样硬化。
Angiotensin （Ang）-（1-7） is recognized as a new bioactive peptide in renin-angiotensin system （RAS）. Ang-（1-7） is a counter-regulatory mediator of Ang-II which appears to be protective against cardiovascular disease. Recent studies have found that Ang-（1-7） played an important role in reducing smooth muscle cell proliferation and migration, improving endothelial function and regulating lipid metabolism, leading to inhibition of atherosclerotic lesions and increase of plaque stability. Although clinical application of Ang-（1-7） is restricted due to its pharmacokinetic properties, identification of stabilized compounds, including more stable analogues and specific delivery compounds, has enabled clinical application of Ang-（1-7）. In this review, we discussed recent findings concerning the biological role of Ang-（1-7） and related mechanism during atherosclerosis development. In addition, we highlighted the perspective to develop therapeutic strategies using Ang-（1-7） to treat atherosclerosis.
基金
This work was supported by National Natural Science Foundation of China （NSFC） （No. 81400265 and No. 81270274）, and Peking University People＇s Hospital Research and Development funds （RDB2014-16）.
